Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients hospitalized with COVID-19-Reference-Cited by-同舟云学术

Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients hospitalized with COVID-19

Published:2023-09 Issue:9 Volume:26 Page:107597
ISSN:2589-0042
Container-title:iScience
language:en
Short-container-title:iScience

Author:

Shivram Haridha,Hackney Jason A.,Rosenberger Carrie M.,Teterina Anastasia,Qamra Aditi,Onabajo Olusegun,McBride Jacqueline,Cai Fang,Bao Min,Tsai Larry,Regev Aviv,Rosas Ivan O.,Bauer Rebecca N.^ORCID

Funder

BARDA

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference61 articles.

1. COVID-19 in early 2021: current status and looking forward;Wang;Signal Transduct. Target. Ther.,2021

2. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis;Shankar-Hari;JAMA,2021

3. Dexamethasone in hospitalized patients with Covid-19;Lim;N. Engl. J. Med.,2021

4. Immunology of COVID-19: current state of the science;Vabret;Immunity,2020

5. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease;McGonagle;Autoimmun. Rev.,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An exploratory analysis of associations of genetic variation with the efficacy of tocilizumab in severe COVID-19 patients. A pharmacogenetic study based on next-generation sequencing;Frontiers in Pharmacology;2024-09-13

2. The Functional Roles of MDSCs in Severe COVID-19 Pathogenesis;Viruses;2023-12-23

3. A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signaling;iScience;2023-10